InterGenetics, Incorporated Craig D. Shimasaki, Ph.D. President and Chief Executive Officer 800 Research Parkway Suite 390 Oklahoma City, OK 73104 Phone: 405/271-1720 FAX: 405/271-1725 www.intergenetics.com InterGenetics, a genetic cancer risk intervention company, is emerging as an innovator in the frontier of genetic medicine. The InterGenetics' research team has discovered proprietary gene combinations and DNA assessment technology leading to the first broad genetic predictive test for breast cancer. The OncoVue™ test analyzes gene combinations responsible for DNA repair, cell cycle control, hormone metabolism, and carcinogen metabolism among others. These combinations, in conjunction with personal history and environmental factors determine a woman’s age specific and lifetime risk for developing sporadic breast cancer – the kind of cancer not associated with a strong family history. In fact, family history accounts for less than 10% of the actual breast cancer cases. The OncoVueTM Breast Cancer Risk Test determines a woman’s lifetime and age specific risk potentially years before diagnosis. By knowing this information, women can take preventative medications to prevent the disease occurrence or the woman and her physician can determine the most appropriate screening regimen to catch cancer at its earliest stages where long term survival is the greatest. OncoVueTM will be launched in mid 2005 through the Breast Cancer Risk Testing Network, a network consisting of premiere comprehensive breast care centers. The participants in this network all share a common goal of early identification and early intervention to provide better outcomes for women who are genetically predisposed to breast cancer. InterGenetics has a promising research pipeline of predictive tests for other cancers such as colon, prostate, and ovarian cancer. The company's core research has future application in predicting heart disease, diabetes and in enhancing the effectiveness of drug therapies and preventative medicine in these fields. For more information about InterGenetics or OncoVueTM Breast Cancer Risk Testing, visit the website at www.intergenetics.com or call 405.271.1720.